These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 18602948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D.
    Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E.
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Stress in women: metabolic syndrome and polycystic ovary syndrome.
    Diamanti-Kandarakis E, Economou F.
    Ann N Y Acad Sci; 2006 Nov; 1083():54-62. PubMed ID: 17148733
    [Abstract] [Full Text] [Related]

  • 9. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C.
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.
    Araujo Penna I, Canella PR, Vieira CS, Silva de Sá MF, dos Reis RM, Ferriani RA.
    Fertil Steril; 2007 Aug; 88(2):519-22. PubMed ID: 17418836
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V.
    Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
    Barber TM, Vojtechova P, Franks S.
    Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
    [Abstract] [Full Text] [Related]

  • 16. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall'Alda M, Spiazzi G, Zanolin ME, Bonora E.
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diagnostic criteria in polycystic ovary syndrome.
    Legro RS.
    Semin Reprod Med; 2003 Aug; 21(3):267-75. PubMed ID: 14593549
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.
    Lambrinoudaki I.
    Maturitas; 2011 Jan; 68(1):13-6. PubMed ID: 20943333
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.